LLY

Eli Lilly and Company

78
Fundamentals85/ 100
Valuation62/ 100
Upside potential72/ 100
Risk potential15/ 100

LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.

SILO

Silo Pharma, Inc.

There isn't enough reported data to score SILO yet.

LLY Fundamentals

MetricStatus
Healthy
Strong
Strong
Healthy

LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.

SILO Fundamentals

MetricStatus
Weak
Under pressure
Under pressure
Unavailable

SILO's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.

LLY PE Valuation

CHEAPFAIREXPENSIVE37x74x111x147x
CHEAPFAIREXPENSIVE37x74x111x147x
LevelPEPriceVs current
Cheap27x$845-41%
Forward30x$1,427โ€”
Current46x$1,427โ€”
Fair48x$1,466+2.7%
Expensive85x$2,612+83%

Historical ranges are pointers, not guarantees.

LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.

SILO PE Valuation

SILO has no meaningful PE right now: it lost money over the past year.

LLY Forward outlook

MetricOutlook
Strongly improving
Strong growth
Strong growth
Strongly improving
Limited
Moderate

Analysts expect strong earnings and revenue growth for LLY, with profitability improving.

SILO Forward outlook

There aren't enough analyst estimates for SILO to show an outlook.

LLY Risk to reward

ScenarioChangePrice
Upside+39%$1,988.49
Downside-15%$1,209.08

Calculated from the latest close: $1,427.28 on Nov 12.

There is not enough scenario data to compare LLY and SILO's risk to reward.

SILO Risk to reward

ScenarioChangePrice
UpsideUnknownโ€”
DownsideUnknownโ€”

Calculated from the latest close: $1.91 on Nov 12.

There is not enough scenario data to compare LLY and SILO's risk to reward.

LLY Earnings Per Share

Q4 2023: $5.80Q1 2024: $6.79Q2 2024: $8.12Q3 2024: $9.25Q4 2024: $11.71Q1 2025: $12.29Q2 2025: $15.30Q3 2025: $20.44Q4 2025: $22.95Q1 2026: $28.15Q2 2026: $29.80Q3 2026: $30.81Forward: $46.82
Q4 2023: $5.80Q1 2024: $6.79Q2 2024: $8.12Q3 2024: $9.25Q4 2024: $11.71Q1 2025: $12.29Q2 2025: $15.30Q3 2025: $20.44Q4 2025: $22.95Q1 2026: $28.15Q2 2026: $29.80Q3 2026: $30.81Forward: $46.82
QuarterTTM EPSYoY
Forward$46.82+52%
Q3 2026$30.81+51%
Q2 2026$29.80+95%
Q1 2026$28.15+129%
Q4 2025$22.95+96%
Q3 2025$20.44+121%
Q2 2025$15.30+88%
Q1 2025$12.29+81%
Q4 2024$11.71+102%

LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus SILO down 177%.

SILO Earnings Per Share

Q3 2023: $-30.32Q4 2023: $-18.02Q1 2024: $-17.87Q2 2024: $-17.72Q3 2024: $-17.87Q4 2024: $-17.85Q1 2025: $-17.10Q2 2025: $-15.30Q3 2025: $-13.80
Q3 2023: $-30.32Q4 2023: $-18.02Q1 2024: $-17.87Q2 2024: $-17.72Q3 2024: $-17.87Q4 2024: $-17.85Q1 2025: $-17.10Q2 2025: $-15.30Q3 2025: $-13.80
QuarterTTM EPSYoY
Q3 2025-$13.80+$4.07
Q2 2025-$15.30+$2.42
Q1 2025-$17.10+$0.77
Q4 2024-$17.85+$0.17
Q3 2024-$17.87+$12.45
Q2 2024-$17.72+$16.80
Q1 2024-$17.87+$19.35
Q4 2023-$18.02+$14.85

SILO is still losing money, but far less than before: $13.80 per share over the past year, against $52.50 at its worst in mid-2020.

LLY Quarterly Revenue

Q4 2023: $9.4BQ1 2024: $8.8BQ2 2024: $11.3BQ3 2024: $11.4BQ4 2024: $13.5BQ1 2025: $12.7BQ2 2025: $15.6BQ3 2025: $17.6BQ4 2025: $19.3BQ1 2026: $19.8BQ2 2026: $23BQ3 2026: $24.4B
Q4 2023: $9.4BQ1 2024: $8.8BQ2 2024: $11.3BQ3 2024: $11.4BQ4 2024: $13.5BQ1 2025: $12.7BQ2 2025: $15.6BQ3 2025: $17.6BQ4 2025: $19.3BQ1 2026: $19.8BQ2 2026: $23BQ3 2026: $24.4B
QuarterRevenueYoY
Q3 2026$24.4B+39%
Q2 2026$23B+48%
Q1 2026$19.8B+56%
Q4 2025$19.3B+43%
Q3 2025$17.6B+54%
Q2 2025$15.6B+38%
Q1 2025$12.7B+45%
Q4 2024$13.5B+45%

LLY has the edge over SILO on sales, with more consistent year-over-year improvement.

SILO Quarterly Revenue

Q3 2023: $18,025Q4 2023: $18,026Q1 2024: $18,026Q2 2024: $18,025Q3 2024: $18,025Q4 2024: $18,026Q1 2025: $18,026Q2 2025: $18,025Q3 2025: $18,025Q4 2025: $18,026Q1 2026: $18,026Q2 2026: $0
Q3 2023: $18,025Q4 2023: $18,026Q1 2024: $18,026Q2 2024: $18,025Q3 2024: $18,025Q4 2024: $18,026Q1 2025: $18,026Q2 2025: $18,025Q3 2025: $18,025Q4 2025: $18,026Q1 2026: $18,026Q2 2026: $0
QuarterRevenueYoY
Q1 2026$18K0%
Q4 2025$18K0%
Q3 2025$18K0%
Q2 2025$18K0%
Q1 2025$18K0%
Q4 2024$18K0%
Q3 2024$18K0%
Q2 2024$18K0%

SILO's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.

LLY Free Cash Flow

Q4 2023: โˆ’$1.4BQ1 2024: $180MQ2 2024: $241MQ3 2024: $2.4BQ4 2024: $978MQ1 2025: $156MQ2 2025: $1.4BQ3 2025: $6.7BQ4 2025: $678MQ1 2026: $3BQ2 2026: $7.8BQ3 2026: $8.2B
Q4 2023: โˆ’$1.4BQ1 2024: $180MQ2 2024: $241MQ3 2024: $2.4BQ4 2024: $978MQ1 2025: $156MQ2 2025: $1.4BQ3 2025: $6.7BQ4 2025: $678MQ1 2026: $3BQ2 2026: $7.8BQ3 2026: $8.2B
QuarterFree cash flowYoY
Q3 2026$8.2B+22%
Q2 2026$7.8B+458%
Q1 2026$3B+1826%
Q4 2025$677.9M-31%
Q3 2025$6.7B+186%
Q2 2025$1.4B+476%
Q1 2025$156.1M-13%
Q4 2024$977.8M+$2.4B

LLY has the edge over SILO on cash generation, producing positive trailing cash flow while its opponent burns cash.

SILO Free Cash Flow

Q3 2023: โˆ’$1MQ4 2023: โˆ’$910,012Q1 2024: โˆ’$838,179Q2 2024: โˆ’$731,803Q3 2024: โˆ’$1MQ4 2024: โˆ’$917,432Q1 2025: โˆ’$2MQ2 2025: โˆ’$1MQ3 2025: โˆ’$955,493Q4 2025: โˆ’$780,278Q1 2026: โˆ’$822,623Q2 2026: โˆ’$781,861
Q3 2023: โˆ’$1MQ4 2023: โˆ’$910,012Q1 2024: โˆ’$838,179Q2 2024: โˆ’$731,803Q3 2024: โˆ’$1MQ4 2024: โˆ’$917,432Q1 2025: โˆ’$2MQ2 2025: โˆ’$1MQ3 2025: โˆ’$955,493Q4 2025: โˆ’$780,278Q1 2026: โˆ’$822,623Q2 2026: โˆ’$781,861
QuarterFree cash flowYoY
Q2 2026-$781.9K+$503.4K
Q1 2026-$822.6K+$817.7K
Q4 2025-$780.3K+$137.2K
Q3 2025-$955.5K+$391K
Q2 2025-$1.3M-$553.5K
Q1 2025-$1.6M-$802.1K
Q4 2024-$917.4K-$7.4K
Q3 2024-$1.3M-$274.7K

SILO has burned cash in almost every quarter: โˆ’$3M over the past year, against โˆ’$5M the year before.

LLY Total Shares

Q4 2023: 903MQ1 2024: 904MQ2 2024: 904MQ3 2024: 905MQ4 2024: 904MQ1 2025: 901MQ2 2025: 900MQ3 2025: 899MQ4 2025: 899MQ1 2026: 896MQ2 2026: 894MQ3 2026: 893M
Q4 2023: 903MQ1 2024: 904MQ2 2024: 904MQ3 2024: 905MQ4 2024: 904MQ1 2025: 901MQ2 2025: 900MQ3 2025: 899MQ4 2025: 899MQ1 2026: 896MQ2 2026: 894MQ3 2026: 893M
PeriodChange %Net change
Quarterly0%-300K shares
1 year-0.6%-5.4M shares
3 years-0.7%-6.4M shares
5 years-1.9%-17.4M shares
Available history-4.5%-42.3M shares

LLY has the edge over SILO on shareholder dilution, with a more favorable share count trend.

SILO Total Shares

Q3 2023: 207,253Q4 2023: 205,325Q1 2024: 191,129Q2 2024: 203,511Q3 2024: 286,790Q4 2024: 245,359Q1 2025: 298,964Q2 2025: 418,649Q3 2025: 622,090Q1 2026: 913,947Q2 2026: 1M
Q3 2023: 207,253Q4 2023: 205,325Q1 2024: 191,129Q2 2024: 203,511Q3 2024: 286,790Q4 2024: 245,359Q1 2025: 298,964Q2 2025: 418,649Q3 2025: 622,090Q1 2026: 913,947Q2 2026: 1M
PeriodChange %Net change
Quarterly+20%+185K shares
1 year+267%+800K shares
3 years+422%+888K shares
5 years+876%+986K shares
Available history+3411%+1.1M shares

SILO has 1M diluted shares, up 267% from a year ago.

LLY Net Leverage

Q4 2023: 2.8xQ1 2024: 2.6xQ2 2024: 2.4xQ3 2024: 2.4xQ4 2024: 2.1xQ1 2025: 2.3xQ2 2025: 2.0xQ3 2025: 1.3xQ4 2025: 1.3xQ1 2026: 1.2xQ2 2026: 1.3xQ3 2026: 1.2x
Q4 2023: 2.8xQ1 2024: 2.6xQ2 2024: 2.4xQ3 2024: 2.4xQ4 2024: 2.1xQ1 2025: 2.3xQ2 2025: 2.0xQ3 2025: 1.3xQ4 2025: 1.3xQ1 2026: 1.2xQ2 2026: 1.3xQ3 2026: 1.2x
QuarterNet LeverageStatus
Q3 20261.2xHealthy
Q2 20261.3xHealthy
Q1 20261.2xHealthy
Q4 20251.3xHealthy
Q3 20251.3xHealthy
Q2 20252.0xHealthy
Q1 20252.3xModerate
Q4 20242.1xModerate

LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.

SILO Net Leverage

SILO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.

LLY Weekly Momentum

MetricValueStatus
RSI68.3Neutral
Stochastic84.1Overbought

LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).

SILO Weekly Momentum

MetricValueStatus
RSI34.7Neutral
Stochastic12.9Oversold

SILO's weekly RSI is 35 (neutral) and its Stochastic is 13 (oversold).

LLY PE vs Healthcare Sector

MetricLLYSector medianRelative
PE46x26x79% above
PE %482919 pts above

LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.

SILO PE vs Healthcare Sector

MetricSILOSector medianRelative
PEN/A26xโ€”

SILO has no meaningful PE right now: it lost money over the past year.

LLY Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$1,279.412% above
20 week MA$1,218.817% above
50 week MA$1,102.229% above
100 week MA$954.150% above
200 week MA$797.579% above

LLY has the edge over SILO on trend strength, trading above more of its moving averages.

SILO Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$1.4433% above
20 week MA$2.7731% below
50 week MA$4.5858% below
100 week MA$8.9179% below
200 week MA$17.489% below

SILO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 89% below its 200-week average.

LLY Yearly ROI

YearStart priceEnd priceROI
2020$131.5$166.7+27%
2021$166.7$273.1+64%
2022$273.1$367.9+35%
2023$367.9$582.9+58%
2024$582.9$783.2+34%
2025$783.2$1,077.8+38%
2026 YTD$1,077.8$1,427.3+32%

LLY has the edge over SILO on returns for 2026, with the stronger performance.

SILO Yearly ROI

YearStart priceEnd priceROI
2021$262.5$101.3-61%
2022$101.3$45.0-56%
2023$45.0$21.6-52%
2024$21.6$14.1-35%
2025$14.1$5.47-61%
2026 YTD$5.47$1.91-65%

SILO has finished every year since 2021 lower, and it's down 65% so far in 2026.

Give your agent the market.

Get API key